XLIFE-SCIENCES-AG
Xlife Sciences AG and Solothurn-based anfass Life Technologies AG have entered a joint venture. Hence, the jointly founded Quadira Biosciences AG has access to the 3D CoSeedis(TM) technology platform of abc biopply ag. This unique 3D cell technology enables the replication of human tissue for reliable testing and characterization of antibodies without animal testing. Xlife's technology platform for the development of antibodies will be used even more efficiently.
As of today, Xlife Sciences AG has already identified 30 compounds with blockbuster potential with its antibody screening platform. These therapeutic antibodies have already shown to be safe and effective in humans. Xlife can modify these antibodies with utmost accuracy and increase the quality of the active ingredient. These are mainly advanced, highly potent antibodies with higher cytotoxic activity and improved side effect profile for cancer therapy. The target market potential of the pre-selected antibodies is in the range of several billion US dollars.
With the collaboration of abc biopply, a portfolio company of anfass Life Technologies, the development process will be advanced significantly. Abc biopply developed a technology platform 3D CoSeedis(TM) that allows the testing and characterization in terms of efficacy of antibodies in 3D- cell cultures, also known as organoids, which are similar to animal or human tissue. This reduces or even eliminates animal testing and accelerates product development significantly. 3D CoSeedis(TM) differentiates itself with its unique homogeneity of produced spheroids and allows standardized mass production. This leads to simplified preclinical modelling of diseases. With this sustainable joint-venture, Quadira Biosciences AG could revolutionize cancer therapy.
About anfass Life Technologies AG
anfass Life Technologies AG invests in promising technologies in the fields of biotech, medical technology and diagnostics. The company also provides strategic and operational support to start-ups and SMEs in the life science sector and offers access to a broad expertise and a reliable network of selected partners. www.anfass.ch
abc biopply ag is a portfolio company of anfass Life Technologies AG. www.biopply.com
.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
IMPORTANT NOTE: The Annual General Meeting of Xlife Sciences AG will now take place on May 11, 2021, due to the Covid-19 measures of the federal government in written form by letter.
Language: |
English |
Company: |
Xlife Sciences AG Klausstrasse 19 8008 Zürich Switzerland |
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich EQS |
News ID: |
1173329 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006227/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches RG660QA and RG660QB 5G Modules With Advanced Performance Features7.1.2026 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the RG600QA and RG660QB 5G module, based on the Qualcomm® X85 and X82 5G Modem-RF Systems. The RG660QA is based on X85 while the RG660QB is based onX82. Engineering samples of two first SKUs in the RG660Qx series have been already made available to customers and pre-production samples will be available to the market in Q2 2026. Designed for versatility, this module series supports a broad array of next generation 5G use cases, from home and business wireless broadband to mobile video, camera applications, and high-performance mobile hotspots. In indoor 5G CPE, it unlocks premium performance by enabling Wi-Fi 7 across the 2.4 GHz, 5 GHz, and 6 GHz bands, with integrated Bluetooth to support a full ecosystem of connected devices. With Ethernet speeds reaching up to 10 Gbps, the RG660Qx delivers the high-capacity backbone needed to power ultra-fast, reliable home and enterprise networks.
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom